期刊文献+

淋巴瘤的免疫治疗进展 被引量:2

Advances of immunotherapy in lymphoma
原文传递
导出
摘要 近年来淋巴瘤的发病率逐渐上升,已经成为最常见的恶性肿瘤之一.新的化疗方案、单克隆抗体、小分子靶向药物等治疗方式已经显著改善了淋巴瘤患者的生存.但是,淋巴瘤患者出现复发或耐药的比例仍然很高,因此针对这些患者寻找新的治疗方式至关重要.细胞免疫治疗可以通过引发特异有效的抗肿瘤免疫反应杀灭肿瘤.继承性细胞免疫疗法、免疫调节药物、免疫检查点治疗等免疫治疗方式在复发/难治淋巴瘤患者的治疗中取得了显著的疗效,逐渐开启了淋巴瘤治疗的新时代. Over the past years, the incidence of lymphoma has been increasing, which has become one of the most common cancers around the world.The survival of lymphoma patients has been significantly improved due to advances of therapeutic methods such as new chemotherapy regimens, monoclonal antibodies and small molecular targeted drugs.However, the number of patients with relapsed/refractory lymphoma still account for a large proportion.It is of great significance to find new ways to treat these patients.Cellular immunotherapy could kill tumor cells by causing specific and effective antitumor immune response.Remarkable advances have been made in immunotherapy, such as adoptive immunotherapy, immune checkpoint inhibitors and immunomodulation therapy, for relapsed/refractory lymphoma patients, which will gradually open a new era in the treatment of lymphoma.
作者 郏博 石远凯
出处 《白血病.淋巴瘤》 CAS 2015年第10期577-579,共3页 Journal of Leukemia & Lymphoma
基金 国家科技支撑计划(2014BA109812)
关键词 淋巴瘤 免疫治疗 免疫调节 免疫检查点 Lymphoma Immunotherapy Immunomodulation Immune checkpoint
  • 相关文献

参考文献3

二级参考文献31

  • 1Sehn LH,Berry B,Chhanabhai M,et al.The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP[J].Blood,2007,109:1857-1861.
  • 2Khouri IF,Saliba RM,Erwin WD,et al.Nonmyeloablative allogeneic transplantation with or without 90yttrium ibritumomab tiuxetan is potentially curative for relapsed follicular lymphoma:12-year results[J].Blood,2012,119:6373-6378.
  • 3Bacher U,Klyuchnikov E,Le-Rademacher J,et al.Conditioning regimens for allotransplants for diffuse large B-cell lymphoma:myeloablative or reduced intensity?[J].Blood,2012,120:4256-4262.
  • 4van Besien K.Current status of allogeneic transplantation for aggressive non-Hodgkin lymphoma[J].Curr Opin Oncol,2011,23:681-691.
  • 5Hoyos V,Savoldo B,Dotti G.Genetic modification of human T lymphocytes for the treatment of hematologic malignancies[J].Haematologica,2012,97:1622-1631.
  • 6Kalos M,Levine BL,Porter DL,et al.T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia[J].Sci Transl Med,2011,3:95ra73.
  • 7Park TS,Rosenberg SA,Morgan RA.Treating cancer with genetically engineered T cells[J].Trends Biotechnol,2011,29:550-557.
  • 8Kowolik CM,Topp MS,Gonzalez S,et al.CD28 costimulation provided through a CD19-specific chimeric antigen receptor enhances in vivo persistence and antitumor efficacy of adoptively transferred T cells[J].Cancer Res,2006,66:10995-11004.
  • 9SongDG,Ye Q,Carpenito C,et al.In vivo persistence,tumor localization,and antitumor activity of CAR-engineered T cells is enhanced by costimulatory signaling through CD137 (4-1BB)[J].Cancer Res,2011,71:4617-4627.
  • 10Savoldo B,Ramos CA,Liu E,et al.CD28 costimulation improves expansion and persistence of chimeric antigen receptor-modified T cells in lymphoma patients[J].J Clin Invest,2011,121:1822-1826.

共引文献444

同被引文献10

引证文献2

二级引证文献5

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部